SC 13G: NLS Pharmaceutics Ltd.

AI Summary

SC 13G filing by NLS Pharmaceutics Ltd..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• sch13g.htm (SC 13G) — 66KB
• exhibit99-1.htm (EX-99.1) — 6KB
• 0000929638-24-001262.txt ( ) — 73KB

From the Filing

SC 13G 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * NLS Pharmaceuticals Ltd. (Name of Issuer) Common Shares, par value CHF 0.02 per share (Title of Class of Securities) H57830103 (CUSIP Number) March 22, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [x] Rule 13d-1(c) [ ] Rule 13d-1(d) ___________________________________ * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Lind Global Fund II LP 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 4,300,000 6 Shared Voting Power 0 7 Sole Dispositive Power 4,300,000 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 4,300,000(1) 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11 Percent of Class Represented by Amount in Row (9)* 9.9%(2) 12 Type of Reporting Person (See Instructions) PN (1) The reporting person's ownership consists of (i) 3,500,000 common shares, and (ii) 1,750,000 warrants to purchase common shares (the "Warrants"); however, due to the exercise limitations of the Warrants, the reporting person's beneficial ownership has been limited to 4,300,000 shares in the aggregate. (2) Each of the Warrants includes a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company. 1 Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Lind Global Partners II LLC 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 4,300,000 6 Shared Voting Power 0 7 Sole Dispositive Power 4,300,000 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 4,300,000(1) 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11 Percent of Class Represented by Amount in Row (9)* 9.9%(2) 12 Type of Reporting Person (See Instructions) OO (1) The reporting person's ownership consists of (i) 3,500,000 common shares, and (ii) 1,750,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person's beneficial ownership has been limited to 4,300,000 shares in the aggregate. (2) Each of the Warrants includes a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company. 1 Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Jeff Easton 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [x] 3 SEC Use Only 4 Citizenship or Place of Organization. United States Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 4,300,000 6 Shared Voting Power 0 7 Sole Dispositive Power 4,300,000 8 Shared Dispositive Power 0 9 Aggregate Amount Beneficially Owned by Each Reporting Person 4,300,000(1) 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11 Percent of Class Represented by Amount in Row (9)* 9.9%(2) 12 Type of Reporting Person (See Instructions) IN (1) The reporting person's ownership consists of (i) 3,500,000 common shares, and (ii) 1,750,000 Warrants; however, due to the exercise limitations of the Warrants, the reporting person's beneficial ownership has been limited to 4,300,000 shares in the aggregate. (2) Each of the Warrants includes a provision limiting the holder's ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company. Item 1. (a) Name of Issuer NLS Pharmaceuticals Ltd. (b) Address of Issuer's Princi

View Full Filing

View this SC 13G filing on SEC EDGAR